Tandem Diabetes Care (TNDM) Earnings Analysis
Tandem Diabetes Care (TNDM) next reports earnings on 2026-08-06, consensus EPS -0.34 USD. Last quarter (2026-05-07) it beat with EPS -0.3 USD vs -0.46 USD est (+34.8%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -12.09.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TNDM next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.34 USD |
| Revenue estimate | 0.26B |
TNDM earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.3 USD | -0.46 USD | +34.8% | Beat |
| 2026-02-19 | -0.01 USD | -0.05 USD | +80% | Beat |
| 2025-04-30 | -0.67 USD | -0.6 USD | -11.7% | Miss |
| 2025-02-26 | -0.44 USD | -0.25 USD | -76% | Miss |
| 2024-08-01 | -0.47 USD | -0.54 USD | +13% | Beat |
Beat rate: 3/5 (60%) over reported quarters with consensus data.
TNDM valuation and analyst view
| Trailing P/E | -12.09 |
|---|---|
| Trailing EPS | -1.38233 USD |
| Price / book | 8.74 |
| Dividend yield | 0.00% |
| Market cap | 1.15B |
| Analyst consensus | Buy (24 buy / 15 hold / 0 sell) |
| Avg price target | 31.25 USD |
Related research pages
Frequently asked questions
When is Tandem Diabetes Care (TNDM)'s next earnings date?
Tandem Diabetes Care is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.34 USD and revenue estimate of 0.26B.
Did TNDM beat earnings last quarter?
In its 2026-05-07 report, TNDM posted EPS of -0.3 USD versus a -0.46 USD estimate — a beat of 34.8%.
What is TNDM's earnings track record?
Over the last 5 reported quarters with consensus data, TNDM beat estimates 3 times (60%).
What is TNDM's current P/E ratio and EPS?
TNDM trades at a trailing P/E of -12.09 on trailing EPS of -1.382326710235829 USD.
What do analysts rate TNDM?
Analyst consensus is "Buy" across 39 ratings (0 strong buy, 24 buy, 15 hold, 0 sell, 0 strong sell). Average 12-month price target: 31.25 USD.